Clinical trial · Interventional
Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
Secondary Prevention of Venous Thromboembolism in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis (STREAM-Line Study)
NCT06603870CI-TRIAL-00090337STREAM-LinerecruitingPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
This trial seeks to evaluate a management strategy after the acute treatment duration (≥ 3 months of therapeutic anticoagulation) for patients with cancer and catheter-related upper extremity deep vein thrombosis (DVT).
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Catheter-Related Infections | — | UNRESOLVED | — |
| Upper Extremity Deep Vein Thrombosis | — | UNRESOLVED | — |
| Venous Thromboembolism | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anticoagulation Therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Apixaban
- description
- 2.5 mg twice daily
- interventionNames
- Drug: Anticoagulation Therapy
Primary outcomes (1)
- measure
- Venous Thromboembolism (VTE) Rate
- timeFrame
- 6 months
- description
- The rates of symptomatic, objectively confirmed new or recurrent major VTE (proximal upper or lower extremity DVT, segmental or larger pulmonary embolism (PE)) with corresponding 95% Confidence Interval (CI) at 6 months.
Secondary outcomes (11)
- measure
- Major Venous Thromboembolism (VTE) and Major bleeding Rate
- timeFrame
- 3 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Adult patients (≥ 18 years old) with active cancer, defined as cancer (other than localized non-melanoma skin cancer) diagnosed or treated within 6 months, or the presence of metastatic, recurrent, or progressive malignancy, ongoing anticancer therapy, or hematological malignancy not in complete remission. Objectively confirmed catheter-related upper extremity DVT and treated with any standard therapeutic anticoagulation (including LMWH dose reduction to 75% after the first month) for at least 3 months. Able and willing to provide informed consent. Exclusion Criteria: Active bleeding or other reasons for which anticoagulation is contraindicated. Other indications requiring ongoing therapeutic dose of anticoagulation as deemed necessary by treating physicians (such as atrial fibrillation, mechanical heart valve, etc.). Anticoagulation has been permanently stopped or reduced to prophylactic dose for \> 5 days prior to enrollment for any reasons. Pregnancy or breast feeding in patients who are prescribed a direct oral anticoagulant. Concomitant use of strong inhibitors or inducers of both cytochrome P450 3A4 and P-glycoprotein in patients who are prescribed a direct oral anticoagulant. Cancer is in remission and CVC is removed prior to enrollment. Requirement of dual antiplatelet therapies. Platelet count \< 50 x 109/L or creatinine clearance \< 30 ml/min. Life expectancy of less than 3 months.
References
Publications (0)
Data not yet available
No reference posted for this study.